IPH4102 is a monoclonal antibody against kIR3DL2 which is currently being investigated in a phase I clinical trial in patients with relapsed or advanced CTCL (NCT02593045). The gene discussed is KIR3DL2; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.